Education
About Us
Working with TipRanks
Follow Us
Arvinas Holding Company (ARVN)
NASDAQ:ARVN
ARVN Stock Chart & Stats
$13.60
$0.30(1.54%)
At close: 4:00 PM EST
$13.60
$0.30(1.54%)
Day’s Range― - ―
52-Week Range$5.90 - $18.45
Previous CloseN/A
Volume216.17K
Average Volume (3M)819.43K
Market Cap
$877.54M
Enterprise Value$739.05M
Total Cash (Recent Filing)$685.40M
Total Debt (Recent Filing)$8.50M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Apr 30, 2026EPS Estimate
-0.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding63,961,000
10 Day Avg. Volume998,735
30 Day Avg. Volume819,433
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)1.77
Price to Sales (P/S)2.93
P/FCF Ratio-2.79
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue2.81
Enterprise Value/Gross Profit2.83
Enterprise Value/Ebitda-7.59
Forecast
1Y Price Target
$16.00Price Target Upside17.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)-3.38
Revenue Forecast (FY)$91.93M
Bulls Say, Bears Say
Bulls Say
KRAS Oncology ProgramARV-806 targets both active and inactive KRAS G12D, shows potent preclinical tumor-killing activity and synergy with immune checkpoint therapies, supporting its potential as a backbone for combination regimens in difficult cancers.
Neurodegeneration ProgramARV-102 demonstrates dose-dependent brain and cerebrospinal fluid biomarker engagement with favorable tolerability in early human testing, supporting the rationale for a registrational study in progressive supranuclear palsy.
Pipeline ExpansionMultiple phase 1 and preclinical programs are expected to produce clinical data, creating several upcoming catalysts that could broaden development opportunities and increase investor visibility.
Bears Say
Commercial Partner UncertaintyRegulatory filing acceptance for vepdeg was accompanied by mixed efficacy evidence and the company is seeking a third-party commercialization partner, creating uncertainty around market uptake and future revenues.
Safety And Pulmonary RiskLRRK2-targeted therapy has known lung effects that may require long-term pulmonary monitoring, creating a safety and development hurdle that could delay progress.
Valuation And Development RiskAnalyst applies a higher discount rate and neutral terminal growth to reflect increased development risk as the company shifts toward earlier-stage programs, pressuring valuation assumptions.
Arvinas Holding Company News
ARVN FAQ
What was Arvinas Holding Company’s price range in the past 12 months?
Arvinas Holding Company lowest stock price was $5.90 and its highest was $18.45 in the past 12 months.
What is Arvinas Holding Company’s market cap?
Arvinas Holding Company’s market cap is $877.54M.
When is Arvinas Holding Company’s upcoming earnings report date?
Arvinas Holding Company’s upcoming earnings report date is Apr 30, 2026 which is in 53 days.
How were Arvinas Holding Company’s earnings last quarter?
Arvinas Holding Company released its earnings results on Feb 24, 2026. The company reported -$1.1 earnings per share for the quarter, missing the consensus estimate of -$0.513 by -$0.587.
Is Arvinas Holding Company overvalued?
According to Wall Street analysts Arvinas Holding Company’s price is currently Undervalued.
Does Arvinas Holding Company pay dividends?
Arvinas Holding Company does not currently pay dividends.
What is Arvinas Holding Company’s EPS estimate?
Arvinas Holding Company’s EPS estimate is -0.93.
How many shares outstanding does Arvinas Holding Company have?
Arvinas Holding Company has 63,961,000 shares outstanding.
What happened to Arvinas Holding Company’s price movement after its last earnings report?
Arvinas Holding Company reported an EPS of -$1.1 in its last earnings report, missing expectations of -$0.513. Following the earnings report the stock price went up 0.569%.
Which hedge fund is a major shareholder of Arvinas Holding Company?
Currently, no hedge funds are holding shares in ARVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arvinas Holding Company Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.00 (17.65% Upside)
$16.00 (17.65% Upside)
Blogger Sentiment
Bullish
ARVN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 83.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $762.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-24.69%
12-Months-Change
Fundamentals
Return on Equity
-16.23%
Trailing 12-Months
Asset Growth
-34.22%
Trailing 12-Months
Company Description
Arvinas Holding Company
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
ARVN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed strong scientific and clinical momentum—multiple programs advancing, encouraging early biomarker and preclinical signals, and disciplined cost reductions—while simultaneously revealing material financial pressure from a steep decline in cash and a large quarter-over-quarter revenue drop. The company maintained guidance for cash runway into 2028 and emphasized partner discussions, but the balance sheet tightening and competitive landscape create meaningful execution and financing risk alongside the positive clinical developments.View all ARVN earnings summariesARVN Stock 12 Month Forecast
Average Price Target
$16.00
▲(17.65% Upside)
Technical Analysis
AnaptysBio
―
Meiragtx Holdings
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Bicara Therapeutics Inc.
―
Ownership Overview
3.33% Insiders
19.04% Mutual Funds
10.65% Other Institutional Investors
54.00% Public Companies and
Individual Investors